EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).

Tatyasaheb Kore Dental College

Status and phase: Completed; Phase 4

Conditions: Saliva; Periodontitis; Superoxide Dismutase; Etoricoxib; Cyclooxygenase Two Inhibitors

Treatments: Drug: Etoricoxib

Study type: Interventional

Funder types: Other

Identifiers

NCT02149758

sum2141

Details and patient eligibility

About

The hypothesis is that Etoricoxib act as an adjuvant to SRP in alleviating periodontal inflammation by:

1. improving clinical periodontal parameters and,
2. improving the salivary SOD levels.

Enrollment: 40 patients

Sex: All

Ages: 30 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:Forty patients with chronic generalized periodontitis

Exclusion Criteria:with system illnesses, allergies, pregnancy, history of any drug intake and periodontal treatment in past 6 months.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: Quadruple Blind

---

40 participants in 2 patient groups, including a placebo group

Etoricoxib

Experimental group

Description:

Etoricoxib 60 mg once daily

Treatment:

Drug: Etoricoxib

matching placebo

Placebo Comparator group

Description:

matching placebo once daily

Treatment:

Drug: Etoricoxib